WILMINGTON, Mass., Aug. 28, 2014 /PRNewswire/ — Marking a major milestone for the Company, Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 desktop explosives trace detector has successfully completed the certification process for the United States Transportation Security Administration’s (TSA) Explosive Trace Detection (ETD) qualification requirements for aviation checkpoint and checked baggage screening. The QS-B220 becomes the first ETD with a non-radioactive source to be added to the TSA’s Qualified Product List (QPL).

“The addition of the QS-B220 to TSA’s QPL is the single most significant achievement in our Company’s history,” stated Implant Sciences’ President and CEO, Glenn D. Bolduc. “We’re very proud to be able to deliver this innovative product for the protection of travelers in our country. Every member of the Implant Sciences team has done a phenomenal job of getting us to this point. We would also like to recognize the support we have received from our shareholders and other investors over the last few years while we have been pursuing this most significant qualification. Without their support this would not have been achievable.”

“Being added to TSA’s QPL is one of the highest levels of recognition in the security industry and one of the most difficult to achieve. The team at Implant Sciences has been nothing short of remarkable and focused in preparing the QS-B220 for this challenge,” continued Todd Silvestri, VP of Technology for Implant Sciences Corporation. “Implant Sciences has highlighted their deep domain knowledge in the development and commercialization of this unit, and we are excited as a company to have cleared the last major hurdle in the U.S. aviation market.”

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

Pompano Beach, Fla., Sept. 2, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products and specialty pharmaceuticals, today announced it will open its first DS Laboratories Hair Loss Clinic in Miami, Florida. Slated to open in the fourth quarter of 2014, the clinic will provide unique therapies and treatment options for patients who desire the most comprehensive approach to treating hair loss. A team of healthcare professionals led by a medical doctor will provide customized solutions with the most advanced proven technologies developed through DS Healthcare’s clinical research to restore a full head of hair.

“We believe no other company offers the kind of comprehensive hair loss treatment and expertise that will be delivered to patients at our DS Laboratories Hair Loss Clinic. Our commitment to innovation has created a growing portfolio of therapies that are not available anywhere else. The clinics are the ideal platform for DS Healthcare to utilize treatment protocols accumulated through years of clinical research. The clinics will leverage the brand awareness of DS Healthcare with an established target customer base,” stated DS Healthcare President and CEO Daniel Khesin.

According to the Washington Post Americans spend $3.5 billion per year in an attempt to treat hair loss.

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Healthcare Group’s flagship brand, visit www.dslaboratories.com

WILMINGTON, Mass., Sept. 2, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today it has sold $1.2 million worth of trace detectors to a customer in the European Union. The units will be deployed for critical infrastructure protection and homeland security.

“We won this contract in a highly competitive environment. The contract win was a result of our trace detectors exceeding the customer’s expectations, particularly when compared to competitive products, as well as the service and support provided by our superior local distributor,” stated Dr. Darryl Jones, Implant Sciences’ Vice President of Global Sales and Marketing.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company’s team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide. Implant Sciences is only the third manufacturer, and the sole American-owned company, to currently have an ETD system named as a Qualified Product by the US Transportation Security Administration. The Company’s ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland Security Award for “Best Explosives Detection Solution”. All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.

ROCKVILLE, Md.–(BUSINESS WIRE)–

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the United States Patent and Trademark Office for a new delivery technology titled, “Polymeric Systems for the Delivery of Anticancer Drugs”. The patent covers CPMA, a new polymer drug delivery platform technology developed by Rexahn.

“We are pleased to further expand our platform of proprietary drug delivery technologies in preclinical development. CPMA complements our nano-polymer-drug delivery platform, nano-polymer-drug conjugate system (NPDCS), which has already shown promising results in preclinical studies,” stated Rexahn’s CEO, Peter D. Suzdak, Ph.D. “Our drug delivery platforms address a well-recognized need in cancer treatment for drugs that selectively target and kill cancer cells, while leaving healthy cells unharmed. Although numerous widely used FDA-approved anti-cancer drugs offer benefits to patients, in most cases, the efficacy of these drugs can be significantly improved, and their toxic side-effects minimized, if they can be combined with a targeted drug delivery technology to bring the drug directly into cancer cells.”

The CPMA technology platform allows for multiple anti-cancer compounds to be covalently bound to the proprietary polymer backbone and be coupled to a signaling moiety. The signaling moiety directs the bound drug to the cancer cell, thereby bypassing healthy cells leading to enhanced efficacy with the potential for reduced side effects. Once inside the cancer cell the CPMA complex is metabolized yielding the free anticancer compound. Because of its diverse chemical properties, CPMA is highly water soluble which allows water insoluble anti-cancer compounds to be bioavailable through a more effective delivery.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) during August 2014. This brings the total study enrollment to 252 patients.

“Given that summer months generally have a slower rate of enrollment for clinical trials, our goal was to maintain the enrollment level compared to the three months prior to the summer. In fact, we did better. We continue to add more centers and countries to the study. As we head into the fall, we believe the pace of patient enrollment will further increase,” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

About Multikine

Multikine* (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI’s clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body’s natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015. The trial is expected to expand into a total of approximately 100 clinical centers in about 20 countries.

In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the U.S. Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI also announced that it entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.